Spyre Therapeutics (SYRE) Interest & Investment Income (2015 - 2026)
Spyre Therapeutics posted quarterly Interest & Investment Income of $7.0 million for Q1 2026, up 7.73% year-on-year from $6.5 million in Q1 2025, and down 2.02% on a QoQ basis from $7.1 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Interest & Investment Income data on file, last reported at $7.0 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 7.73% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (up 8.62% YoY), and the FY2025 full-year result was $24.9 million, up 16.77% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $7.0 million, down from $7.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.1 million in Q4 2025 and bottomed at $35000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $4.4 million (2024), against an average of $3.5 million.
- The widest annual swing landed in 2024, when Interest & Investment Income surged 1591.43%; it then declined 0.78% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $410000.0 in 2022, then soared by 906.34% to $4.1 million in 2023, then surged by 39.99% to $5.8 million in 2024, then grew by 23.6% to $7.1 million in 2025, then fell by 2.02% to $7.0 million in 2026.
- The last three Interest & Investment Income figures came in at $7.0 million (Q1 2026), $7.1 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 7.14 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Mar 31, 2025 | 6.49 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Sep 30, 2024 | 5.18 Mn |
| Jun 30, 2024 | 5.92 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 4.13 Mn |
| Sep 30, 2023 | 1.25 Mn |
| Jun 30, 2023 | 350,000.00 |
| Mar 31, 2023 | 420,000.00 |
| Dec 31, 2022 | 410,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Jun 30, 2022 | 104,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | 36,000.00 |
| Jun 30, 2021 | 19,000.00 |
| Mar 31, 2021 | 22,000.00 |
| Dec 31, 2020 | 44,000.00 |
| Sep 30, 2020 | 88,000.00 |
| Jun 30, 2020 | 161,000.00 |
| Mar 31, 2020 | 300,000.00 |
| Dec 31, 2019 | 432,000.00 |
| Sep 30, 2019 | 585,000.00 |
| Jun 30, 2019 | 619,000.00 |
| Mar 31, 2019 | 507,000.00 |
| Dec 31, 2018 | 427,000.00 |
| Sep 30, 2018 | 339,000.00 |
| Jun 30, 2018 | 263,000.00 |
| Mar 31, 2018 | 143,000.00 |
| Dec 31, 2017 | 150,000.00 |
| Sep 30, 2017 | 136,000.00 |
| Jun 30, 2017 | 100,000.00 |
| Mar 31, 2017 | 95,000.00 |
| Dec 31, 2016 | 72,000.00 |
| Sep 30, 2016 | 72,000.00 |
| Jun 30, 2016 | 74,000.00 |
| Mar 31, 2016 | 26,000.00 |
| Dec 31, 2015 | 11,000.00 |
| Sep 30, 2015 | 5,000.00 |
| Jun 30, 2015 | 5,000.00 |
| Mar 31, 2015 | 1,000.00 |